Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) traded down 3.5% during trading on Wednesday . The company traded as low as $20.17 and last traded at $20.52, with a volume of 809,894 shares changing hands. The stock had previously closed at $21.26.

A number of equities research analysts recently commented on the stock. Piper Jaffray Cos. restated an “overweight” rating and issued a $22.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 11th. Jefferies Group raised their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. BMO Capital Markets restated a “hold” rating and issued a $17.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Monday, August 1st. Finally, Needham & Company LLC raised their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Amphastar Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $20.00.

The company has a market capitalization of $943.03 million, a P/E ratio of 67.86 and a beta of 1.83. The stock’s 50 day moving average price is $18.56 and its 200-day moving average price is $15.35.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, August 8th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.01 by $0.22. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. The firm earned $68 million during the quarter, compared to analysts’ expectations of $62.10 million. During the same quarter in the prior year, the firm earned ($0.09) EPS. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. Analysts anticipate that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current year.

In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 10,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $19.95, for a total value of $199,500.00. Following the completion of the transaction, the general counsel now owns 212,961 shares in the company, valued at approximately $4,248,571.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 2,297 shares of the company’s stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $17.76, for a total transaction of $40,794.72. Following the completion of the transaction, the chief financial officer now owns 64,652 shares of the company’s stock, valued at approximately $1,148,219.52. The disclosure for this sale can be found here. 29.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AMPH. State Street Corp boosted its position in Amphastar Pharmaceuticals by 3.8% in the first quarter. State Street Corp now owns 662,582 shares of the company’s stock valued at $7,949,000 after buying an additional 24,205 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $180,000. UBS Asset Management Americas Inc. boosted its position in Amphastar Pharmaceuticals by 10.0% in the first quarter. UBS Asset Management Americas Inc. now owns 277,294 shares of the company’s stock valued at $3,328,000 after buying an additional 25,095 shares during the period. Acadian Asset Management LLC boosted its position in Amphastar Pharmaceuticals by 43.4% in the first quarter. Acadian Asset Management LLC now owns 452,371 shares of the company’s stock valued at $5,428,000 after buying an additional 136,816 shares during the period. Finally, Menta Capital LLC purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $533,000. Hedge funds and other institutional investors own 35.87% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.